While cutting-edge therapies grace headlines, the impact of breakthrough research remains limited due to patient access, affordability, and adherence.
Phil and Penny Knight made a record-setting $2 billion gift to OHSU Knight Cancer Institute.
Refocusing cancer R&D for greater impact: Addressing gaps in disparities and access
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Managing director, BrightEdge; Vice president, Innovation and Impact Investing, American Cancer Society
Table of Contents
YOU MAY BE INTERESTED IN
Mary Beckerle, a whitewater kayaker, has advice for all the folks in the cancer field: never catastrophize, never panic.
The Government Accountability Office, an independent, non-partisan congressional watchdog agency, found that NIH violated the Impoundment Control Act of 1974 when it cancelled nearly 2,000 research grants in an effort to comply with several of President Donald Trump’s executive orders, including “Ending Radical And Wasteful Government DEI Programs And Preferencing” (The Cancer Letter, Jan 24, 2025).
EPCORE FL-1 phase III trial results show that subcutaneous epcoritamab in combination with rituximab and lenalidomide reduced the risk of disease progression or death by 79% for patients with relapsed/refractory follicular lymphoma.
The landscape of cancer care is evolving rapidly, with growing recognition that optimal patient outcomes require a whole-person care approach that goes beyond cytotoxic and targeted therapies.
Shane Jacobson was appointed CEO of the American Cancer Society and the American Cancer Society Cancer Action Network.
